王伟,安朝,李宁,乔帆,蔡成良,李白翎,韩林,徐志云,陆方林

• 1:海军军医大学附属长海医院心血管外科

摘要(Abstract)：

本文报告1例行介入三尖瓣置换术的重度导线相关性三尖瓣关闭不全(LITR)患者,在数字减影血管造影、经食管超声心动图引导下全身麻醉行介入三尖瓣置换术,接受LuX-Valve置入后三尖瓣反流完全纠正,术后1、6个月随访结果良好。文献回顾发现3款同类装置,均进入临床试验阶段。提示LuXValve置入是一种可靠有效的重度LITR治疗手段。

关键词(KeyWords)： 介入三尖瓣置换术;三尖瓣反流;起搏器植入

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划（2016YFC1100900）;; 上海市科学技术委员会项目（17441901800）;; 宁波科技局项目科技创新2025重大专项（2018B10092）

作者(Author): 王伟,安朝,李宁,乔帆,蔡成良,李白翎,韩林,徐志云,陆方林

参考文献(References)：

• [1] Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol, 2017, 69(18):2331-2341.
• [2] Mediratta A, Addetia K, Yamat M, et al. 3D echocardiographic location of implantable device leads and mechanism of associated tricuspid regurgitation. JACC Cardiovasc Imaging, 2014, 7(4):337-347.
• [3]成艳，郑良荣.起搏导线相关性三尖瓣关闭不全的研究进展.中华心律失常学杂志，2020, 24(1):82-85.
• [4] Lu F, Qiao F, Lv Y, et al. A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model.Int J Cardiol, 2020,319:120-126.
• [5] Regazzoli D, Ielasi A, Lanzillo G, et al. Sustained reduction of tricuspid regurgitation af ter percutaneous repair with the mitraclip system in a patient with a dual chamber pacemaker. JACC Cardiovasc Interv, 2017, 10(16):e147-e149.
• [6] Braun D, Orban M, Nabauer M, et al. Transcatheter treatment of severe tricuspid regurgitation using the edge-to-edge repair technique in the presence and absence of pacemaker leads. JACC Cardiovasc Interv, 2017, 10(19):2014-2016.
• [7] Lurz J, Rommel KP, Unterhuber M, et al. Safety and e ffi cacy of transcatheter edge-to-edge repair of the tricuspid valve in patients with cardiac implantable electronic device leads. JACC Cardiovasc Interv, 2019, 12(20):2114-2116.
• [8] Taramasso M, Gavazzoni M, Pozzoli A, et al. Outcomes of TTVI in patients with pacemaker or defi brillator leads:data from the trivalve registry. JACC Cardiovasc Interv, 2020, 13(5):554-564.
• [9] Paradis JM, Bernier M, Houde C, et al. Jailing of a pacemaker lead during tricuspid valve-in-valve implantation with an Edwards SAPIEN XT transcatheter heart valve. Can J Cardiol, 2015, 31(6):819.e9-e11.
• [10] Eleid MF, Asirvatham SJ, Cabalka AK, et al. Transcatheter tricuspid valve-in-valve in patients with transvalvular device leads.Catheter Cardiovasc Interv, 2016, 87(4):E160-E165.
• [11] Anderson JH, McElhinney DB, Aboulhosn J, et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. JACC Cardiovasc Interv,2020, 13(17):2012-2020.
• [12] Lu FL, Ma Y, An Z, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13):1614-1616.
• [13] Navia JL, Kapadia S, Elgharably H, et al. Transcatheter tricuspid valve implantation of navigate bioprosthesis in a preclinical model.JACC Basic Transl Sci, 2018, 3(1):67-79.
• [14] Asmarats L, Dagenais F, Bédard E, et al. Transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation:initial experience with the NaviGate Bioprosthesis. Can J Cardiol, 2018,34(10):1370.e5-1370.e7.